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Abstract
Background—Several previous studies have reported that amnestic mild cognitive impairment
(aMCI), a significant risk factor for Alzheimer’s disease (AD), is associated with greater atrophy in
the medial temporal lobe (MTL) and posterior cingulate gyrus (PCG).
Method—In the present study, we examined the cross-sectional accuracy (i.e., the sensitivity and
specificity) of voxel-based morphometry (VBM) in discriminating individuals with MCI (n =15)
from healthy age-matched controls (n =15). In addition, we also sought to determine whether baseline
GM volume predicted aMCI patients that converted to AD from those that did not approximately 2
years after the baseline visit.
Results—MCI patients were found to display significantly less GM volume in several hypothesized
regions including the MTL and PCG relative to the age-matched controls (p < 0.01). Logistic
regression analysis and receiver operating characteristic (ROC) curves for GM volume in the anterior
MTL and PCG revealed high discriminative accuracy of 87%. By contrast, baseline GM volume in
anterior MTL and PCG did not appear to be sensitive to changes in clinical status at the follow-up
visit.
Conclusion—These results suggest that VBM might be useful at characterizing GM volume
reductions associated with the diagnosis of aMCI.
Keywords
Mild cognitive impairment; Alzheimer’s disease; Voxel-based morphometry; Hippocampus;
Posterior cingulate gyrus; Sensitivity and specificity
1. Introduction
Mild cognitive impairment-amnestic type (aMCI) is a term typically used to describe the
earliest stage of Alzheimer’s disease (AD) [1]. Peterson et al. [2] have sought to establish
clinical criterion for the diagnosis of aMCI. These criteria include the presence of subjective
memory complaints preferably corroborated by an informant, objective episodic memory
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impairment (1.5 standard deviations below age-matched normal subjects), intact activities of
daily living, and cognitive/functional status not consistent with the diagnosis of dementia [1].
Using these criterion, the large-scale, multi-center, Alzheimer’s Disease Cooperative Study
found that 212 of 214 (99%) cases of aMCI eventually met the clinical criteria for possible or
probable AD, indicating that the enrollment criteria for aMCI were highly specific [3].
Several recent structural MRI studies using primarily region of interest (ROI) tracing methods
have reported that individuals with aMCI display greater atrophy in the medial temporal lobes
(MTL) relative to age-matched controls [see 4 for review]. Furthermore, longitudinal MRI
studies have found that MTL atrophy was a good predictor of individuals with aMCI who
subsequently developed AD from those who did not over a 3–5 year follow-up periods [5–7].
Recent advances in structural MRI image analysis such as voxel-based morphometry (VBM)
allow an unbiased mapping of gray matter (GM) volume [8]. The automated VBM procedure
has a high degree of reproducibility, and has been previously used to examine GM volume in
both AD and aMCI. These studies generally report findings consistent with observations from
studies using manual ROI or histopathological methods. For example, Karas et al. [9] found
that individuals with aMCI had significantly reduced GM volume in the MTL relative to age-
matched controls. Furthermore, AD patients had significantly less GM volume in both posterior
cingulate gyrus (PCG) and MTL relative to the aMCI and control groups. However, no
differences in GM volume in the PCG were found between the aMCI patients and controls.
Together, these results suggest that VBM might be useful at characterizing neuropathological
changes associated with the early stages of AD.
In the present study, we used VBM to 1) replicate previous findings of regional GM volume
reductions in a group of patients who met the criteria for aMCI, 2) the area under the curve
(AUC) of receiver-operating characteristic (ROC) analysis to determine the sensitivity and
specificity of VBM at separating aMCI patients from age-matched controls, and 3) determine
whether baseline GM volume was associated with longitudinal changes in clinical status in the
aMCI patients. The combined use of different ROIs might result in better accuracy than the
use of one ROI (e.g., hippocampus) alone. Based on previous studies, we hypothesized that




Fifteen individuals were identified that met the Petersen [1] criteria for aMCI. These individuals
were then matched to 15 healthy elderly control participants based on gender, age, and
education (see Table 1). Each group consisted of nine men and six women. All subjects received
a detailed neuropsychological evaluation examining several cognitive domains. aMCI patients
were referred from the several memory disorders clinics at a university-based medical center.
The diagnostic criteria for aMCI were those recommended by Petersen [1] including: a)
presence of memory complaints by the patient that was preferably corroborated by an
informant, b) objective memory impairment defined as performance that was 1.5 SD below
the cutoff for normal aging on at least one of four memory measures, c) essentially intact
activities of daily living, and d) cognitive and functional status not consistent with a diagnosis
of dementia. Prior to inclusion in this study, the aMCI patients were presented to a diagnostic
consensus panel for support of the diagnosis. Longitudinal follow-up data (mean follow-up
interval = 1.83 ± 0.68 years) were available for 12 aMCI patients (80%). Follow-up data for
the majority of the elderly controls was not available because the design of our longitudinal
study is to follow individuals meeting the criterion for aMCI.
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Subjects that met the clinical criterion for multi-domain or non-amnestic MCI were excluded
from the statistical analyses. Additional exclusion criteria for both groups included Hachinski
score greater than four, prior neurological disease or neurosurgery, current diagnosis of major
psychiatric disorder (including depression), or chronic major medical conditions (e.g., diabetes,
poorly controlled hypertension, or cardiac disease). Elderly control participants were recruited
from the community, predominantly by advertisement, mailings, and community outreach
events. Control participants exhibited normal baseline performance across cognitive domains
as assessed by the same battery of neuropsychological measures used to determine cognitive
impairment in the aMCI patients (see Table 1).
2.2. Neuropsychological assessment
The aMCI patients and elderly controls received a battery of neuropsychological tests using
standardized administration procedures. The memory measures used for the diagnosis of aMCI
included long-delay recall and total word recall (trials 1–5) of the Rey Auditory Verbal
Learning Test (RAVLT) or long-delay recall and total recall (trials 1–3) of the Brief
Visuospatial Memory Test-Revised (BVMT-R). The complete battery of neuropsychological
measures included the following tests: RAVLT, BVMT-R, Mini-Mental Status Exam
(MMSE), Judgement of Line Orientation Test (JLO), Controlled Oral Word Fluency Test
(COWAT), Clock Drawing Test, Boston Naming Test (BNT), the Wide Range Achievement
Test-3 (WRAT-3) reading subtest, and Trail Making Tests A and B. Between-group differences
were examined using two-sample t-tests with a Bonferroni-corrected alpha level set at p <
0.005 (i.e., p < 0.05 divided by 12 comparisons).
2.3. Anatomic imaging
All participants were situated on the bed of a GE 3.0 Tesla MRI scanner, and foam padding
was placed on each side of the head to reduce motion related artifacts. A 3D IR-prepped fast
gradient echo pulse sequence was administered to provide high-resolution T1-weighted
structural images. In order to obtain whole-brain coverage, imaging parameters were as
follows: inversion time = 600 ms, fast gradient echo read-out with TR/TE/flip = 9 ms/1.8 ms/
20°; acquisition matrix = 256 × 192 × 124 (axial 256 × 192 in-plane, interpolated to 256 ×
256); FOV = 240 mm; slice thickness = 1.2 mm (124 slices); ± 16 kHz receiver band-width;
acquisition time ~ 7.5 minutes. A neuroradiologist viewed the anatomical images from each
participant for structural abnormalities not consistent with the subject diagnosis and/or
requiring clinical follow-up. The T1-weighted images were then used for the VBM analyses.
2.4. Voxel-based morphometry processing steps & statistical analysis
Analysis of the T1 anatomical images and the subsequent segmentation of these images into
GM, white matter (WM), and cerebrospinal fluid (CSF) were performed with the VBM
approach described by Good et al. [see also 8,10] using Statistical Parametric Mapping (SPM2)
software (http://www.fil.ion.ucl.ac.uk/spm).
2.4.1. Template creation—We created customized GM templates by averaging together
the T1-weighted anatomical scans of the controls and MCI patients. First, all images were
coregistered to the SPM2 T1-weighted template and then partitioned into GM, white matter
(WM), and cerebrospinal fluid (CSF) images. Second, the GM images were normalized to the
SPM2 GM template using affine only transformations. The normalization parameters obtained
for each subject were then reapplied to the original anatomical images. Third, these normalized
images were segmented and extracted, and the GM, WM, and CSF images were averaged
across the subjects. Finally, Gaussian smoothing (isotropic 8-mm full-width-at-half-
maximum) was applied to the mean images to obtain the customized whole-brain template and
GM prior probability images that were subsequently used for the VBM analyses.
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2.4.2. Single-subject, preprocessing steps—The original anatomical image was
segmented into GM, WM, and CSF images, and the GM images were normalized to the custom
GM template with a 15 parameter fit. The normalization parameters were re-applied to the
original image that was re-sampled using B-splines interpolation to a voxel size of 2 mm3. The
normalized brain image was then segmented and the resulting GM images were modulated
using the Jacobian values obtained from the spatial normalization in order to preserve GM
volume. In the final step, the modulated images were smoothed using a 12-mm isotropic
Gaussian kernel.
2.5. Data analysis
2.5.1. VBM group analysis—Smoothed GM images were entered into a random-effects
group analysis using the general linear model to compare differences in GM volume between
the age-matched control group and the aMCI group. We used an ANCOVA design with total
intracranial volume (TICV) as a nuisance variable. Since previous VBM studies in aMCI and
AD patients have reported reduced GM volume in the MTL, PCG, and temporal/parietal
cortices [e.g., 9,e.g., 11,12], we restricted our analyses to these regions of interest (ROI) using
the Wake Forest University Pick Atlas toolbox [13] within SPM2. Due to the relatively small
sample size and the a-priori ROI approach used, between group differences were examined
using an alpha level set at p < 0.01 (uncorrected for multiple comparisons). In a second step,
we used a voxel-level, FDR-corrected threshold (p = 0.05) to further evaluate the presence of
significant differences in GM volume in unhypothesized brain regions [see also 12].
2.5.2. Logistic regression and ROC analysis—The area under the curve (AUC) for
receiver operating characteristic (ROC) analysis was computed to determine whether VBM
could accurately discriminate aMCI patients from age-matched controls. ROC curve analysis
is frequently used as an indicator of the ability of a classification test to discriminate individuals
with and without a disease [14]. The ROC curve examines the true-positive rate (or sensitivity)
relative to the false-positive rate (or 1-specificity). AUC values range from 0.50 (test is no
better than chance) to 1 (test is always accurate). The greater the accuracy of the test the closer
the ROC plot is to the upper left corner.
The a-priori defined ROIs for the VBM group analysis included the PCG and MTL. We then
used the volume of interest (VOI) option in SPM2 to extract adjusted GM volume values from
a 2 mm radius sphere (corresponding to 7 contiguous voxels with a voxel size = 2 mm3 for a
total volume of 56 mm3) centered on the local maxima within the PCG and MTL ROIs. The
GM values were used in a logistic regression analyses to assess whether reduced PCG or MTL
GM volume were significant predictors of the baseline diagnosis of aMCI obtained from the
neuropsychological data. Results were considered significant at an alpha level of p < 0.05.
Statistical analyses were computed with SPSS (version 12).
3. Results
3.1. Neuropsychological and demographic data
There were no significant baseline differences between the two groups in terms of age or
education (p > 0.50). However, chi square analysis for APOE genotype revealed a significantly
greater percentage of APOE ε4 carriers in the aMCI group relative to the control group (χ2 =
19.3, p < 0.01). Furthermore, aMCI patients were significantly impaired relative to the age-
matched control group for the MMSE, RAVLT long delay recall and total word recall (trials
1–5), BVMT long delay recall and total recall (trials 1–3), and Trails Making Test B. Although
the performance of the aMCI patients on Trail Making Test B was within age-adjusted, normal
limits. There were no significant differences between the two groups after correction for
multiple comparisons for the other neuropsychological test measures (see Table 1).
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3.2. VBM data - group comparison
The VBM group analysis revealed several areas where local GM volume was reduced in the
aMCI group relative to the control group (Fig. 1, Table 2). We found that aMCI patients
displayed greater atrophy relative to the control group in hypothesized regions including left
PCG, left anterior MTL (AMTL), left hippocampus/parahippocampal gyrus (HPC/PHG), and
the right temporal (middle and inferior) gyrus. The follow-up whole-brain analysis did not
reveal any additional significant regions of reduced GM volume after correction for multiple
comparisons. Given the large range of age in both the aMCI and age-matched groups, the
analysis was redone with age and TICV as nuisance variables and a similar pattern of reduced
GM volume was observed. In contrast, there were no regions in which the aMCI group
displayed significantly greater GM volume relative to the control group even at the more liberal
threshold of p < 0.05 (uncorrected). These results replicate the findings of previous studies that
have demonstrated GM volume reductions in the PCG and MTL of individuals with aMCI.
3.3. Logistic Regression and ROC curve analysis
The logistic regression model testing the contribution of AMTL, PCG, and HPC/PHG GM
VOIs to discriminate MCI patients from age-matched controls revealed that all three values
were independent predictors of group assignment (B=−4.02, SE = 1.61, p = 0.01 for the AMTL
VOI; B = −7.61, SE = 3.0, p = 0.01 for PCG VOI; and B = −1.93, SE = 0.83, p = 0.02 for the
HPC/PHG VOI). GM volume in the AMTL was the best predictor of group assignment
(accuracy = 83%) with a sensitivity and specificity of 87% and 80%, respectively. The AUC
for the ROC curve analysis was 0.88, 95% C.I., 0.74–1.01. The accuracy of the aMCI diagnosis
for the PCG VOI was 73% (sensitivity and specificity were both 73%). The AUC for the ROC
curve analysis within the PCG VOI was 0.81, 95% C.I., 0.66–0.97. In contrast, the GM volume
in the HPC/ PHG cluster was much less predictive of the MCI diagnosis with 60% accuracy,
67% sensitivity, 53% specificity, and an AUC for the ROC curve analysis of 0.79 (95% C.I.,
0.63–0.95). When both the AMTL and PCC GM values were included in the analysis, the
overall accuracy of discrimination improved to 87% (AUC = 0.88) (see Fig. 2).
3.5. Longitudinal follow-up
Longitudinal follow-up neuropsychological and clinical data were available for 12 of 15 (80%)
aMCI patients that received baseline MRI scans. Of the 12 aMCI patients, 3 had converted to
AD based on NINCDS-ADRDA criterion and 2 displayed a worsening in function, but still
did not meet the clinical criterion for AD. The cognitive status of the remaining 7 aMCI patients
remained relatively stable over the follow-up period.
A second logistic regression within the aMCI patient group with clinical status at the follow-
up visit (i.e., convert to AD versus stable aMCI) was done to determine if baseline GM volume
at each of the 3 VOIs used in the baseline logistic regression were predictive of the conversion
of aMCI to AD. The GM volume values for each of the 3 VOIs and the clinical status at the
follow-up visit for each of the aMCI patients can be seen in Fig. 3. The GM volume values for
the vast majority of the aMCI patients was below the mean of the control group at all 3 VOIs
(14/15 for AMTL and HPC/PHG VOIs and 13/15 for the PCG VOI) (see Fig. 3). The GM
volume of subjects that declined from aMCI to AD were each below the mean of the elderly
controls, but were not consistently less than the baseline GM volume of the aMCI patients that
were stable at follow-up. This was confirmed by our failure to demonstrate that baseline GM
volume from the 3 VOIs was able to discriminate (p’s > 0.35) between aMCI patients that
remained stable versus those that converted to AD.
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The present study used VBM to: 1) examine regional differences in GM volume in individuals
with aMCI relative to age-matched controls, 2) determine the sensitivity and specificity of
VBM-based measures at discriminating between aMCI patients and age-matched controls, and
3) to determine whether baseline GM volume predicted those aMCI patients that declined to
AD at the follow-up visit.
We found that aMCI patients displayed reduced GM volume relative to the age-matched
controls in several brain regions previously reported to display volumetric declines in AD and
aMCI. aMCI patients displayed reduced GM volume in the MTL (including hippocampus,
amygdala, and fusiform gyrus), the PCG , and the right middle and inferior temporal gyri. The
left AMTL was found to display the most significant reductions in GM volume in our group
of aMCI patients.
These findings are consistent with previous VBM studies of aMCI and AD, which have
generally found the most significant GM volume reductions in the MTL. For example, Karas
et al. [9] reported the most significant reductions in GM volume in the hippocampus, amygdala,
and middle temporal gyrus of both MCI and AD patients [see also 11,15]. These findings are
also consistent with ROI studies of MTL volume. Bottino et al. [9] reported that AD patients
had significant bilateral reductions in GM volume in the hippocampus, amygdala, and
parahippocampal gyrus relative to MCI patients and healthy, control subjects. MCI patients
were found to display significant, left-lateralized reductions in GM volume in these same
regions relative to controls. Similar findings have been reported by several previous studies
[11,12,16–19].
We also found that individuals with aMCI displayed reduced GM volume in the PCG. These
findings are also consistent with recent ROI tracing studies, which have also reported volume
reductions in the PCG of AD patients [20,21]. Previous VBM studies in aMCI have reported
conflicting findings regarding GM volume reductions in this region. For example, Chetelat et
al. [11] reported reduced GM volume in the PCG of aMCI patients, whereas Karas et al. [9]
did not find any differences between aMCI patients and controls [see also 15]. However, AD
patients were found to have significantly less GM volume in the MTL, PCG and parietal
association cortices relative to aMCI patients. The exact reason for these conflicting findings
is not known, and might be due to differences in the diagnostic criterion used for aMCI [22]
or other technical issues (e.g., different field strength MRI scanners or differences in the
statistical thresholds employed). Reduced GM volume in the PCG might also suggest that some
of the aMCI patients in the present study were closer to AD than others (in fact 3 aMCI patients
were found to have converted to AD at the follow-up visit). This would also be consistent with
the findings that performance on non-memory measures (i.e., Trail Making Test B) was also
significantly poorer in the aMCI group.
In the present study, GM volume in the AMTL and PCG VOIs were found to be better
independent predictors of group assignment than GM volume in the HPC/PHG VOI. When
both AMTL and PCG GM VOIs were entered into the logistic regression model, accuracy of
correctly classifying individuals as aMCI versus controls improved to 87%. These findings are
consistent with Bottino et al. [23], who correctly classified 88% of the AD patients relative to
controls, 82% of AD patients relative to aMCI subjects, and 81% of the MCI subjects relative
to controls when manually-traced ROIs of the amygdala, hippocampus and para-hippocampal
gyrus were included together in the regression model. Testa et al. [24] used both manual ROI
and automated VBM measures of MTL GM volume in AD, and found that VBM was superior
to the ROI based method at distinguishing between AD patients and age-matched controls [see
also 17,18].
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Previous studies that have examined the diagnostic accuracy of only hippocampal GM volume
measurements at classifying aMCI patients versus controls have reported poor diagnostic
accuracy (i.e., 68 – 73%) [see 4 for review], consistent with the findings of the present study.
The poor accuracy observed using hippocampal volumetric measurements may reflect
heterogeneity in episodic memory impairment used to diagnose MCI [4] or the presence of
reduced hippocampal volume in the control group used for comparison. It is also possible that
the better discriminative ability of the AMTL might be due to the fact that the AMTL VOI was
more likely to be in a general block of tissue in the MTL than the HPC/PHG VOI, possibly
due to variability in the size/shape of MTL subregions associated with normal aging or aMCI.
This variability in regional brain morphology might therefore reduce the accuracy of spatial
normalization thereby reducing the power of VBM to detect group differences. For example,
Mosconi et al. [25] found that only 3% of the hippocampus displayed 100% overlap using
voxel-based methods similar to the present study. In any case, the baseline HPC/PHG VOI
obtained from the VBM analysis in the present study did not appear to adequately distinguish
aMCI subjects from normal controls. Therefore, the results of the present study are consistent
with previous findings [23], indicating that the combined use of regional ROIs is more sensitive
than a single ROI to the clinical diagnosis of aMCI.
Longitudinal studies have reported that reductions in hippocampal volume over time were
predictive of those MCI patients that converted to AD from those that did not [see 4 for review].
More recently, Chetelat et al. [26] conducted a longitudinal VBM study of GM volume
comparing MCI patients that converted to AD versus those that did not. These authors reported
that over an 18-month follow-up period, both AD converters and non-converters displayed GM
loss in temporal and parahippocampal gyri, orbitofrontal and inferior parietal areas, and the
left thalamus. In contrast, AD converters displayed significantly greater GM loss relative to
non-converters in the hippocampus, inferior and middle temporal gyrus, posterior cingulate,
and precuneus during the follow-up period. Together, these results suggest that structural and
functional changes in both hippocampus and PCG are predictive of the conversion from MCI
to AD.
This study has several limitations that reduce the generalizability of the present findings. First,
the brain regions used for the sensitivity and specificity analysis were biased by our a-priori
knowledge of brain regions in which our group of aMCI patients displayed significantly less
GM volume. Future studies will be able to examine sensitivity and specificity of the clinical
diagnosis of aMCI, and whether regional GM volume can predict conversion to AD with the
VOIs used in this study or those reported by others [17,18,24,27], preferably with larger sample
sizes. Second, despite our rigorous inclusion and exclusion criterion for both groups, it is quite
possible that some of the aMCI patients were not in the early stages of AD, since a small
percentage of individuals diagnosed with possible or probable AD are found on autopsy to
have other neurodegenerative dementias [e.g., 28]. Therefore, it is possible that some of the
aMCI patients in our study were not in the early stages of AD. Longitudinal VBM studies
similar to the study by Chetelat et al. [26] would be useful in determining whether or not aMCI
patients that convert to AD display a different pattern of longitudinal decline in regional GM
volume relative to aMCI patients that do not rapidly convert to AD. Despite these limitations,
the results of the present study indicate that the combined use of GM volume in the AMTL
and PCG had better discriminative ability for aMCI than either region alone.
In summary, the present study found that aMCI patients displayed reduced GM volume in
several regions such as PCG, MTL, and medial and inferior temporal gyri previously reported
to display volumetric declines in aMCI and/or AD. These findings are consistent with previous
histopathological and MRI based ROI studies. Logistic regression and ROC curve analysis
revealed that GM volume from VOIs in the AMTL and PCG were better predictors of group
assignment, and the combined use of AMTL and PCG VOIs produced greater accuracy (87%)
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than either measure alone. However, baseline GM volume in aMCI patients was not found to
be a significant predictor of individuals with aMCI who subsequently developed AD versus
those that did not at least over the 2-year follow-up period used in the present study.
More longitudinal studies similar to the present study that combine neuropsychological
assessment with structural MRI to examine the time course of pathological changes in PCG
and MTL are needed to determine the relationship between structural and cognitive changes
in AD. Along with several previous VBM studies, our results suggest that VBM might provide
a relatively simple tool for staging the progressive structural changes associated with the AD
disease process in vivo.
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Regions of greater GM volume in controls relative to aMCI patients. Statistical parametric
maps of the VBM analysis representing regions in which age-matched control subjects
displayed greater GM volume relative to individuals with aMCI at a threshold of p < 0.01
(uncorrected) rendered on the customized GM template used in the VBM pre-processing steps.
The left side of the image corresponds to left, and the right side of the image corresponds to
the right.
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baseline ROC curve analysis Receiver operating characteristics (ROC) curve of the VBM based
AMTL and PCG GM volume measures to separate 15 aMCI patients from 15 controls.
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Plot of baseline GM volume for the aMCI and elderly control groups Baseline GM volume
from the AMTL, HPC/PHG, and PCG VOIs used for the ROC curve analysis with the clinical
status at follow-up for aMCI patients and elderly controls with follow-up data. The x = control
group, o = stable aMCI at follow-up visit, Δ = aMCI conversion to AD + = follow-up clinical
status unknown.
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Table 1
Demographic and neuropsychological data
Controls MCI
Mean SD Mean SD
Age (years) 73.6 7.1 73.3 6.72
Education (years) 16.7 2.5 16.3 2.81
Gender Ratio: Female / Male 6/9 6/9
% APOE e4 carriers * 17% 54%
MMSE † 29.7 0.5 27.8 1.8
RAVLT total recall trials 1–5 † 46.8 6.5 30.5 5.2
RAVLT long delay recall † 8.9 1.8 1.9 1.9
BVMT total recall trials 1–3† 23.5 8.0 12.8 5.3
BVMT long delay recall† 9.3 1.8 4.3 2.8
Boston Naming Test 57 3.2 55.7 3.6
COWAT adjusted raw score 46.5 8.9 37.5 9.7
Clock Drawing Test 9.6 1.3 9.4 0.5
JLO Test 25.7 3.01 25.7 3.03
Trail Making Test A (sec) 33.7 7.6 42.2 18.6
Trail Making Test B (sec)‡ 65.9 15.7 92.8 22.5
WRAT-3 reading subtest – Standard Score 118.7 19.7 110.3 7.8
Note: Unless otherwise indicated, all data represent raw scores and are presented as mean (SD).
MMSE =Mini Mental Status Exam, BVMT =Brief Visual Memory Test, COWAT =Controlled Oral Word Fluency Test, JLO = Judgement of Line
Orientation Test, RAVLT = Rey Auditory Verbal Learning Test, BNT = Boston Naming Test, WRAT = Wide Range Achievement Test-3. See text for
further discussion of test measures.
*
significant difference (p < .01)
†
significant difference (p < 0.0001)
‡
significant difference (p < 0.001).







































































































































































































































Alzheimers Dement. Author manuscript; available in PMC 2008 November 18.
